TY - JOUR
T1 - The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer
AU - Rehfeld, Nina
AU - Geddert, Helene
AU - Atamna, Abedelsalam
AU - Rohrbeck, Astrid
AU - Garcia, Guillermo
AU - Kliszewski, Slawek
AU - Neukirchen, Judith
AU - Bruns, Ingmar
AU - Steidl, Ulrich
AU - Fenk, Roland
AU - Gabbert, Helmut E.
AU - Kronenwett, Ralf
AU - Haas, Rainer
AU - Rohr, Ulrich Peter
PY - 2006/1/20
Y1 - 2006/1/20
N2 - Background: PTTG-1 (pituitary tumor transforming gene) is a novel oncogene that is overexpressed in tumors, such as pituitary adenoma, breast and gastrointestinal cancers as well as in leukemia. In this study, we examined the role of PTTG-1 expression in lung cancer with regard to histological subtype, the correlation of PTTG-1 to clinical parameters and relation on patients' survival. Methods: Expression of P TTG-1 was examined immunohistochemically on formalin-fixed, paraffin-embedded tissue sections of 136 patients with, small cell lung cancer (SCLC) and 91 patients with non-small cell lung cancer (NSCLC), retrospectively. The intensity of PTTG-1 expression as well as the proportion of PTTG-1 positive cells within a tumor was used for univariate and multivariate analysis. Results: PTTG-1 expression was observed in 64% of SCLC tumors and in 97.8% of NSCLC tumors. In patients with SCLC, negative or low PTTG-1 expression was associated with a shorter mean survival time compared with patients with strong PTTG-1 expression (265 ± 18 days vs. 379 ± 66 days; p = 0.0291). Using the Cox regression model for multivariate analysis, PTTG-1 expression was a significant predictor for survival next to performance status, tumor stage, LDH and hemoglobin. In contrast, in patients with NSCLC an inverse correlation between survival and PTTG-1 expression was seen. Strong PTTG-1 expression was associated with a shorter mean survival of 306 ± 58 days compared with 463 ± 55 days for those patients with no or low PTTG-1 intensities (p = 0.0386). Further, PTTG-1 expression was associated weith a more aggressive NSCLC phenotype with an advanced pathological stge, extensive lymph node metastases, distant metastases and increased LDH level. Multivariate analysis using Cox regression confirmed the prognostic relevance of PTTG-1 expression next to performance status and tumor stage in patients with NSCLC. Conclusion: Lung cancer belong to the group of tumors expressing PTTG-1. Dependent on the histological subtype of lung cancer, PTTG-1 expression was associated with a better outcome in patients with SCLC and a rather unfavorable outcome for patients with NSCLC. These results may reflect the varying role of PTTG-1 in the pathophysiology of the different histological subtypes of lung cancer.
AB - Background: PTTG-1 (pituitary tumor transforming gene) is a novel oncogene that is overexpressed in tumors, such as pituitary adenoma, breast and gastrointestinal cancers as well as in leukemia. In this study, we examined the role of PTTG-1 expression in lung cancer with regard to histological subtype, the correlation of PTTG-1 to clinical parameters and relation on patients' survival. Methods: Expression of P TTG-1 was examined immunohistochemically on formalin-fixed, paraffin-embedded tissue sections of 136 patients with, small cell lung cancer (SCLC) and 91 patients with non-small cell lung cancer (NSCLC), retrospectively. The intensity of PTTG-1 expression as well as the proportion of PTTG-1 positive cells within a tumor was used for univariate and multivariate analysis. Results: PTTG-1 expression was observed in 64% of SCLC tumors and in 97.8% of NSCLC tumors. In patients with SCLC, negative or low PTTG-1 expression was associated with a shorter mean survival time compared with patients with strong PTTG-1 expression (265 ± 18 days vs. 379 ± 66 days; p = 0.0291). Using the Cox regression model for multivariate analysis, PTTG-1 expression was a significant predictor for survival next to performance status, tumor stage, LDH and hemoglobin. In contrast, in patients with NSCLC an inverse correlation between survival and PTTG-1 expression was seen. Strong PTTG-1 expression was associated with a shorter mean survival of 306 ± 58 days compared with 463 ± 55 days for those patients with no or low PTTG-1 intensities (p = 0.0386). Further, PTTG-1 expression was associated weith a more aggressive NSCLC phenotype with an advanced pathological stge, extensive lymph node metastases, distant metastases and increased LDH level. Multivariate analysis using Cox regression confirmed the prognostic relevance of PTTG-1 expression next to performance status and tumor stage in patients with NSCLC. Conclusion: Lung cancer belong to the group of tumors expressing PTTG-1. Dependent on the histological subtype of lung cancer, PTTG-1 expression was associated with a better outcome in patients with SCLC and a rather unfavorable outcome for patients with NSCLC. These results may reflect the varying role of PTTG-1 in the pathophysiology of the different histological subtypes of lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=32044463313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32044463313&partnerID=8YFLogxK
U2 - 10.1186/1477-3163-5-4
DO - 10.1186/1477-3163-5-4
M3 - Article
AN - SCOPUS:32044463313
SN - 1477-3163
VL - 5
JO - Journal of Carcinogenesis
JF - Journal of Carcinogenesis
ER -